NasdaqGS:AUTLBiotechs
Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials
Autolus Therapeutics recently reported preliminary unaudited 2025 net product revenue of about US$75 million and issued 2026 guidance of US$120 million to US$135 million, alongside progressing obe-cel into Phase 2 trials for lupus nephritis and other indications.
The company also secured UK and EU approvals for AUCATZYL®, pairing early commercial traction with expanding clinical data in both pediatric oncology and autoimmune disease.
Next, we’ll examine how this combination of higher revenue...